

DFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Patent No.	Application No.	Filing Date	Attorney Docket
TBD	10/764,371	January 23, 2004	DOVP-1-0603

**POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST
(REVOCATION OF PRIOR POWERS)**

TO THE COMMISSIONER OF PATENTS:

As assignee of record of the entire interest in the patents and patent serial numbers identified above, and which appear in more detail in Exhibit A of the Certificate Under 37 CFR § 3.73(b) attached hereto and incorporated by reference,

REVOCATION OF PRIOR POWERS OF ATTORNEY

all powers of attorney previously given are hereby revoked, and

NEW POWER OF ATTORNEY

the practitioners associated with the Customer Number provided below are hereby appointed with full power of substitution and revocation to prosecute and transact all business in the Patent and Trademark Office connected therewith.

Customer Number 25315

SEND CORRESPONDENCE TO:

Jeffrey J. King
BLACK LOWE & GRAHAM ^{PLLC}
701 Fifth Avenue, Suite 4800
Seattle, WA 98104


DIRECT TELEPHONE CALLS TO:

Jeffrey J. King
Telephone: 206.381.3300
Facsimile: 206.381.3301

Respectfully submitted,

DOV PHARMACEUTICAL, INC.

Dated: JAN. 31, 2006

By 
Leslie Hudson, President
Chief Executive Officer



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.	Application No.	Issue Date	Attorney Docket
TBD	10/764,371	January 23, 2004	DOVP-1-0603 (Formerly 2370-006-06)

**CERTIFICATE UNDER 37 CFR § 3.73(b)
ESTABLISHING RIGHT OF ASSIGNEE TO TAKE ACTION**

1. The assignee of the entire right, title and interest in the properties identified in Exhibit A attached hereto, hereby seeks to take action in the PTO in this matter.

IDENTIFICATION OF ASSIGNEE

2. DOV PHARMACEUTICAL, INC., a Delaware Corporation

PERSON AUTHORIZED TO SIGN

3. I, the person signing below, aver that I am empowered to sign this statement on behalf of the assignee.

BASIS OF ASSIGNEE'S INTEREST

4. Ownership by the assignee of the patent/serial number identified in Exhibit A attached hereto and incorporated by reference is established as follows:


1. An assignment from the inventor of the matter identified above,
which was recorded in the PTO at

Reel/Frame: 012130/0575 on August 24, 2001


I, Leslie Hudson, have reviewed all the documents in the chain of title to the patent application identified herein and, to the best of my knowledge and belief, title is in the assignee identified above.

I hereby declare that all the statements made herein of my own knowledge are true, and that all statements made on information and beliefs are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

DOV PHARMACEUTICAL, INC.



Leslie Hudson, President
Chief Executive Officer



Jeffrey J. King
Registration No.: 38,515
Black Lowe & Graham, PLLC
701 Fifth Avenue, Suite 4800
Seattle, WA 98104
Telephone: 206.381.3300
Facsimile: 206.381.3301

EXHIBIT A

Title: **(-)-1-(3,4-dichlorophenyl)-3-axabicyclo[3.1.0]hexane,
Compositions Thereof, And Uses As A Dopamine-
Reuptake Inhibitor**

Patent No.: 6,716,868
Serial No.: 10/425,545
Issue Date: April 6, 2004
Filing Date: August 21, 2004
Inventors: LIPPA, Arnold S.; EPSTEIN, William J.